46th week of 2013 patent applcation highlights part 40 |
Patent application number | Title | Published |
20130302203 | METHOD OF MANUFACTURING A BEARING - A method of manufacturing a bearing includes, firstly, injecting a mixture of metal powder into a mold to form a semi-finished product. Then the semi-finished product is sintered. After that, the sintered semi-finished product is fine machined, and then washed, to form the bearing. | 2013-11-14 |
20130302204 | HIGH CARBON STEEL WIRE ROD EXCELLENT IN DRAWABILITY AND FATIGUE CHARACTERISTICS AFTER WIRE DRAWING - High performance high carbon wire with refined inclusions after wire rolling, extremely low wire breakage rates at the time of drawing even in tough applications, and excellent in fatigue characteristics after wire drawing, characterized by having a predetermined composition of ingredients and in that the number ratio of inclusions satisfying (% SiO | 2013-11-14 |
20130302205 | High Purity Copper and Method of Producing High Purity Copper Based on Electrolysis - High purity copper having a purity of 6N or higher, wherein content of each of the respective components of P, S, 0, and C is 1 ppm or less, and nonmetal inclusions having a particle size of 0.5 μm or more and 20 μm or less contained in the copper are 10,000 inclusions/g or less. As a result of using high purity copper or high purity copper alloy as the raw material from which harmful P, S, C, O-based inclusions have been reduced and controlling the existence form of nonmetal inclusions, it is possible to reduce the occurrence of rupture of a bonding wire and improve the reproducibility of mechanical properties, or reduce the percent defect of a semiconductor device wiring formed by sputtering a high purity copper target with favorable reproducibility. | 2013-11-14 |
20130302206 | 2XXX SERIES ALUMINUM LITHIUM ALLOYS - New 2xxx aluminum lithium alloys are disclosed. The aluminum alloys include 3.5-4.4 wt. % Cu, 0.45-0.75 wt. % Mg, 0.45-0.75 wt. % Zn, 0.65-1.15 wt. % Li, 0.1-1.0 wt. % Ag, 0.05-0.50 wt. % of at least one grain structure control element, up to 1.0 wt. % Mn, up to 0.15 wt. % Ti, up to 0.12 wt. % Si, up to 0.15 wt. % Fe, up to 0.10 wt. % of any other element, with the total of these other elements not exceeding 0.35 wt. %, the balance being aluminum. | 2013-11-14 |
20130302207 | STERILIZATION WITH IN-LINE CONCENTRATING AND INJECTION OF HYDROGEN PEROXIDE - In a hydrogen peroxide gas plasma sterilizer, the concentration of the hydrogen peroxide sterilant is an important factor in determining sterilization efficacy. The present application describes sterilizers, and sterilization methods, which use a novel injector-concentrator arrangement. This arrangement provides accurate control of concentration of the liquid-phase hydrogen peroxide, prior to vaporization of the liquid sterilant into the sterilization chamber. This increases the reliability and efficacy of the sterilization cycle. | 2013-11-14 |
20130302208 | COLD-MIST DECONTAMINATION UNIT AND METHOD OF OPERATING SAME - A method of decontaminating a room or space, comprising the steps of providing a cold-mist decontamination device capable of generating an atomized mist comprised of a decontaminant and water, inputting into an internal processor the parameters of the room or space and the concentration of the decontaminant in the decontamination solution, measuring the temperature and humidity in the room or space, and determining the maximum amount of the decontamination solution that can be introduced into the room or space in atomized form without condensing the decontaminant on surfaces within the room or space. | 2013-11-14 |
20130302209 | High Efficiency Solid-State Light Source and Methods of Use and Manufacture - A high-intensity light source is formed by a micro array of a semiconductor light source such as a LEDs, laser diodes, or VCSEL placed densely on a liquid or gas cooled thermally conductive substrate. The semiconductor devices are typically attached by a joining process to electrically conductive patterns on the substrate, and driven by a microprocessor controlled power supply. An optic element is placed over the micro array to achieve improved directionality, intensity, and/or spectral purity of the output beam. The light module may be used for such processes as, for example, fluorescence, inspection and measurement, photopolymerzation, ionization, sterilization, debris removal, and other photochemical processes. | 2013-11-14 |
20130302210 | CORROSION INHIBITOR COMPOSITIONS, METHODS FOR MAKING AND METHODS FOR USING - A method for inhibiting corrosion on metallic surfaces in contact with a liquid hydrocarbon media is provided. A corrosion inhibitor composition is dispersed into a liquid hydrocarbon media to form a protective film on the metallic surfaces. The corrosion inhibitor includes a polyamic acid having structure I: | 2013-11-14 |
20130302211 | LIQUID PRODUCT PRESSURE TREATMENT METHOD AND DEVICE - A method and device related to a liquid product pressure and (optionally) temperature treatment method reduces the level of microorganisms in the liquid product to a preselected level. Utilizing the method, liquid product is diffused in a chamber with the speed of pressure variation of liquid product in one embodiment of about 10 | 2013-11-14 |
20130302212 | AUTOMATIC ANALYZER - The invention provides an automatic analyzer having a scattered-light detecting optical system in which a light source is disposed at an angle with respect to a plane of a reaction vessel. This reduces the amount of a sample-reagent mix required for an analysis, thereby reducing the running cost of reagents as well, and also allows relatively free design of reaction vessels in terms of their sizes and shapes. The automatic analyzer includes: a reaction vessel in which a sample is caused to react with a reagent; a reaction disk on which to place reaction vessels in the form of a circle; a reaction disk rotating mechanism for rotating the reaction disk; a light source for radiating light to be measured onto one of the reaction vessels; and a photodetector for detecting transmissive light radiated from the light source and passing through a sample-reagent mix in the one of the reaction vessels. The automatic analyzer further includes an optical system for causing the light source to radiate light onto one of the reaction vessels at an angle with respect to a plane of the one of the reaction vessels. | 2013-11-14 |
20130302213 | SEPARATION OF MULTI-COMPONENT FLUID THROUGH ULTRASONIC ACOUSTOPHORESIS - An acoustic standing wave is utilized to separate components from a multi-component fluid, such as oil from an oil-water mixture, in a fluid flow scheme with an acoustophoresis device. For example, the flow scheme and device allows for trapping of the oil as the oil coalesces, agglomerates, and becomes more buoyant than the water. | 2013-11-14 |
20130302214 | COATED DIESEL PARTICLE FILTER - The present invention relates to a diesel particle filter which has a coating active in oxidation catalysis and which is characterized in that said diesel particle filter comprises a material zone which removes platinum traces contained in the exhaust-gas flow, and to the use of said diesel particle filter in the purification of exhaust gases of diesel engines. | 2013-11-14 |
20130302215 | COMBINATION DIELECTRIC BARRIER DISCHARGE REACTOR - A combination dielectric barrier discharge reactor includes a rectangular or cylindrical electrically insulative housing and a plurality of reactor units arranged in a parallel or series manner in the housing in a rectangular or circular array. Each reactor unit includes a hollow cylindrical electrode and a rod electrode extending along the longitudinal axis of the hollow cylindrical electrode and a DC working voltage 6 kv-500 kv applied to each reactor unit between the respective hollow cylindrical electrode and the respective rod electrode. The combination dielectric barrier discharge reactor is a modularized structure constructed subject to actual requirements, practical for decomposing waste lubricating oil, insulation oil, milling oil and smokes discharged from a kitchen, smoking room, motor vehicle or machine. | 2013-11-14 |
20130302216 | SYSTEM AND PROCESS FOR PRODUCING AN OXIRANE - Embodiments of the present disclosure are directed to a system and a process for producing an oxirane. For the various embodiments, the system and process of the present disclosure includes: a reaction vessel having a reaction mixture of an olefin, a peroxide compound, a solvent mixture with an alcohol and a non-reactive co-solvent, a solid phase, and reaction products of the reaction mixture, where the reaction products include an oxirane; a separation vessel coupled to the reaction vessel, where an effluent of the reaction mixture and reaction products from the reaction vessel separates in the separation vessel into a liquid aqueous phase and a liquid organic phase; and an extraction vessel coupled to an outlet of the separation vessel, where the liquid aqueous phase taken from the outlet of the separation vessel mixes with an extraction solvent to extract oxirane from the aqueous phase. | 2013-11-14 |
20130302217 | HEATING MODULE, HEATING SYSTEM INCLUDING A PLURALITY OF HEATING MODULES, AND FACILITY INCLUDING SUCH A HEATING SYSTEM - A heating module for heating solid matter, such as balls, to a determined temperature. The module includes a heating pot including a crucible for receiving the matter to be heated, and a burner for heating the crucible and the matter to be heated; and a cover that is mounted in removable manner on the heating pot so as to close the crucible. | 2013-11-14 |
20130302218 | COMPOSITIONS, METHODS AND DEVICES FOR CONTROL AND CLEAN-UP OF HAZARDOUS SPILLS - Disclosed are methods for treating hazardous materials, such as those which result from an unwanted spill or leak, which comprise one or more of the steps or effects of: neutralizing the dispersed material; solidifying the dispersed material; immobilizing the material; and/or reducing the evolution of harmful or unwanted gaseous forms from the spillage, preferably using a binding agent which comprises a polyacrylate-polyacrylamide cross-linked copolymer. | 2013-11-14 |
20130302219 | DEVICE FOR COLLECTING ORAL FLUID SAMPLES AND THE LIKE - Devices for collection and elution of oral fluid samples and the like enable collection and elution of samples by using a handle in the form of a rod having a collection pad thereon which is inserted into a collection tube. The collection tube has an adaptor with a narrowed portion associated therewith for squeezing the pad to wring a sample therefrom. In an alternative embodiment, the collection tube has a narrowed portion that squeezes the pad as the pad is inserted there though. Caps are provided to 1) support the rod in an assembly with the adaptor and collection tube to form an assembled sample collection device and 2) to close the collection tube after the handle and pad are removed from the collection tube subsequent to depositing the sample elution solution therein. The eluted sample can be used for detection of an analyte. | 2013-11-14 |
20130302220 | CONTROLLED PRESSURE RELEASE VESSEL FOR MICROWAVE ASSISTED CHEMISTRY - A controlled release and self-resealing vessel assembly for high pressure microwave assisted chemistry is disclosed. The vessel assembly includes a microwave-transparent, heat expandable reaction vessel having at least two cylindrical portions axially adjacent one another, with one of the portions having a diameter larger than the diameter of the other portion. A transition portion is between the two cylindrical portions, the vessel mouth is in the larger-diameter portion, and a cylindrical retaining sleeve surrounds the vessel. | 2013-11-14 |
20130302221 | HAND-HELD MEDICAL DEVICE - Disclosed herein are hand-held medical devices, such as blood glucose meters, that include a housing with a cassette compartment for receiving an exchangeable test tape cassette, a drive assembly comprising an electric motor and a gear arrangement adapted for rotating a tape spool of the test tape cassette, where the gear arrangement has a worm drive in which a worm meshes with a worm wheel and a multistage speed-reducing unit comprising a plurality of spur gears arranged between the worm wheel and an output gear that can be directly coupled to the tape spool. | 2013-11-14 |
20130302222 | Synthetic Gas Generator - The invention relates to an apparatus for generating synthetic gas, comprising a POX reactor with a first reaction chamber, into which a carbon-containing gaseous feedstock, as well as an oxidizing agent, can be introduced via a feeding system, and a discharge system, whereby a gasification product can be withdrawn from the reaction chamber. The apparatus further contains at least one further, i.e., a second, reaction chamber with a second feeding system, which is connected to the first reaction chamber via the discharge system. | 2013-11-14 |
20130302223 | Recycling Batteries Having Basic Electrolytes - Embodiments related to recycling alkaline batteries are disclosed. In one disclosed embodiment, a method for recycling a battery having a basic electrolyte comprises rupturing the battery under anaerobic conditions and flooding the interior of the battery with carbon dioxide in an anaerobic chamber. | 2013-11-14 |
20130302224 | Selective Regeneration of Isotope-Specific Media Resins in Systems for Separation of Radioactive Isotopes from Liquid Waste Materials - Processes, systems, and methods for selectively regenerating an ion exchange resin generally comprises washing the ion exchange resin with an elution agent that encourages only selected contaminants, and especially selected radioactive isotopes, to disengage or decouple from the resin and enter solution in the elution agent, which thereafter is identified as the elution agent solution. The elution agent solution is then passed through a column of isotope-specific media (ISM). When the selected radioactive isotopes within the elution agent solution come into contact with the constituent media isotopes of the ISM, the selected radioactive isotopes are retained on the reactive surface areas of the ISM or within the interstitial spaces of the porous structures of the constituent media isotopes of the ISM. In some embodiments, the constituent media isotopes of the ISM are embedded, impregnated, or coated with the specific radioactive isotope that the particular ISM are adapted to separate. | 2013-11-14 |
20130302225 | Compositions And Methods Of Using A Ketoxime In A Metal Solvent Extraction Reagent - Provided are methods using a ketoxime in metal extraction. One aspect of the invention relates to a method for the recovery of metal from a metal-containing aqueous solution at an elevated temperature using a ketoxime. Another aspect relates to a method of separating iron/copper using a specific ketoxime. Aldoximes may also be added to the reagent compositions used in these methods. | 2013-11-14 |
20130302226 | METHOD AND APPARATUS FOR RECYCLING LITHIUM-ION BATTERIES - Cathode material from exhausted lithium ion batteries are dissolved in a solution for extracting the useful elements Co (cobalt), Ni (nickel), Mn (manganese), Li (lithium), and Fe (iron) to produce active cathode materials for new batteries. The solution includes compounds of desirable materials such as cobalt, nickel and manganese dissolved as compounds from the exhausted cathode material of spent cells. Depending on a desired proportion, or ratio, of the desired materials, raw materials are added to the solution to achieve the desired ratio of the commingled compounds for the recycled cathode material for new cells. The desired materials precipitate out of solution without extensive heating or separation of the desired materials into individual compounds or elements. The resulting active cathode material has the predetermined ratio for use in new cells, and avoids high heat typically required to separate the useful elements because the desired materials remain commingled in solution. | 2013-11-14 |
20130302227 | PURIFICATION OF TiCl4 THROUGH THE PRODUCTION OF NEW CO-PRODUCTS - The present disclosure relates to reacting tin metal with crude TiCl | 2013-11-14 |
20130302228 | PURIFICATION OF TiCl4 THROUGH THE PRODUCTION OF NEW CO-PRODUCTS - The present disclosure relates to reacting tin metal with crude TiCl | 2013-11-14 |
20130302229 | SPRAY DRYER ABSORPTION APPARATUS WITH FLAT-BOTTOMED CHAMBER - In the application a spray dryer absorption apparatus for treating a stream of flue gas containing acidic components is disclosed. The apparatus comprises a chamber having vertical cylindrical walls, said chamber comprises (i) an inlet for a flue gas stream containing an acidic component, (ii) an atomizer for spraying droplets of an absorbent slurry into said flue gas stream to effect a chemical reaction between the droplets and the acidic component of the flue gas, thereby forming a particulate reaction product, and (iii) an outlet for the treated flue gas and entrained particulate reaction product, wherein the bottom of the chamber having vertical cylindrical walls is substantially horizontal and impervious to gases. The apparatus of the invention has the advantage of a simplified geometry accounting for lower building and maintenance costs. | 2013-11-14 |
20130302230 | Method for Producing Metal Oxide Compositions and Coated Substrates - The present invention generally relates to a process for making a metal oxide composition. The present invention also relates to a process for making a coated metal oxide substrate. | 2013-11-14 |
20130302231 | MULTILAYERED MIXED BED FILTER FOR THE REMOVAL OF TOXIC GASES FROM AIR STREAMS AND METHODS THEREOF - To achieve the removal of a broad spectrum of chemical hazards, multiple layers of impregnated activated carbon and nanocrystalline materials are incorporated into the adsorbent bed. For optimum performance using the least amount of material, a two-layer configuration is used. The top layer consists of a homogeneous mixture of an MgO/CaO based nanocrystalline material (e.g., Mg/Ca) and Kureha or other petroleum pitch-based bead shaped activated carbon impregnated treated with phosphoric acid. The bottom layer is comprised of a single layer of Calgon URC carbon. The volume ratios of the components are 9:5:11 Mg/Ca, phosphoric acid treated Kureha carbon, and URC, respectively. The new configuration leads to a 30% reduction in size of the existing NIOSH CBRN CAP 1 cartridge. Other embodiments are disclosed and claimed. | 2013-11-14 |
20130302232 | METHODS AND SYSTEMS FOR AN ENGINE EMISSION CONTROL SYSTEM - Systems and methods are provided for a layered emission control device coupled to an exhaust manifold. Various formulations may be incorporated in a plurality of layers of the device to enable various emission control functions to be grouped within spatial constraints. For example, a first layer may include a first, oxidizing catalyst, a second layer may include a HC trap, and a third layer may include a second, different oxidizing catalyst, the second layer positioned between the first and third layers. The layers may be organized to reduce functional interference and improve functional synergy between the various emission control functions. | 2013-11-14 |
20130302233 | PROCESS FOR REMOVING MERCAPTANS FROM A GAS STREAM - The present invention provides a process for removing mercaptans from a gas stream. In the process, a first mercaptan-comprising gas stream comprising at least a mercaptan of the general formula: R | 2013-11-14 |
20130302234 | High Capacity Solid Filtration Media - A high capacity filtration media, method of preparing the media, and method of treating a fluid stream with the media are provided. The media contain a porous substrate impregnated with high concentrations of a permanganate. Preferably, the media includes a porous substrate impregnated with at least about 8% permanganate by weight. The media can optionally contain sodium bicarbonate. Improved capacity for the removal of undesirable compounds such as ethylene, formaldehyde, hydrogen sulfide and methyl mercaptan are achieved. | 2013-11-14 |
20130302235 | REMOVING SULFUR DIOXIDE FROM PACKAGING - A sulfur dioxide reducing composition for reducing the headspace concentration of sulfur dioxide in fruit packages includes a sulfur dioxide absorber having pores sized to retain sulfur dioxide therein and a clinching absorber on the sulfur dioxide absorber with which the sulfur dioxide reacts irreversibly with the sulfur dioxide. | 2013-11-14 |
20130302236 | GAMMA RADIATION SOURCE - A gamma radiation source comprises | 2013-11-14 |
20130302237 | Process to produce lithium carbonate direcly from the alumino silicate mineral - Process for obtaining lithium carbonate directly from the mineral containing silicium, aluminium, lithium and other metal oxides without the need to dissolve previously all oxides in sulphuric acid or alkaline hydroxides at high temperatures and pressures, by using carbon dioxide and water at supercritical or near supercritical conditions acting directly on the fine powder of the mineral. | 2013-11-14 |
20130302238 | CONTINUOUS MANUFACTURING APPARATUS AND METHOD FOR CARBON NANOTUBES HAVING GAS SEPARATION UNITS - The present invention relates to a continuous manufacturing apparatus for a carbon nanotube having gas separation units and a continuous manufacturing method for a carbon nanotube using the same, and more specifically, to a continuous manufacturing apparatus for a carbon nanotube having gas separation units and a continuous manufacturing method for a carbon nanotube using the same, in which the apparatus includes i) a reactor for synthesizing the carbon nanotube; ii) a separator for separating a mixed gas and the carbon nanotube transferred from the reactor; iii) a gas separation unit including more than one polymer membrane for removing in part or in whole of more than one component gas from the mixed gas separated; and iv) a recirculation pipe for recirculating the mixed gas without in part or in whole of the component gas to the reactor of carbon nanotube. According to the present invention, the present invention has an effect to provide the continuous manufacturing apparatus of the carbon nanotube and continuous manufacturing method using the same, in which it makes possible to perform a rapid processing; has excellent productivity and excellent conversion rate of carbon source; can significantly reduce the cost of production; can reduce energy consumption because a reactor size can be decreased as compared with capacity; and has a gas separation unit that not generate a waste gas. | 2013-11-14 |
20130302239 | METHOD FOR MAKING A CHALCOPYRITE-TYPE COMPOUND - A method for making a chalcopyrite-type compound includes reacting a reaction mixture in a solvent under a reaction temperature and a reaction pressure to form the chalcopyrite-type compound. The reaction mixture includes at least one first compound and at least one second compound. The first compound contains M | 2013-11-14 |
20130302240 | METHOD FOR PURIFICATION OF SPENT SULFURIC ACID FROM TITANIUM DIOXIDE RUTILE INDUSTRY - A method for the purification of spent sulfuric acid and particularly the purification of spent acid, from titanium dioxide rutile manufacture through a chloride route, is provided. In the chloride route of titanium dioxide manufacture, sulfuric acid is used to clean the un-reacted gaseous flow coming out of the oxidizer, so the spent acid mainly contains un-reacted Ti | 2013-11-14 |
20130302241 | CATALYST FOR HYDROGEN PRODUCTION - The invention provides a catalyst for the production of hydrogen by steam reforming. The catalyst is a porous catalyst which is based on at least aluminium oxide and preferably magnesium oxide, and further comprises boron and nickel. The porous catalyst comprises pores having an average pore size in the range of 0.1-50 nm. The activity of the catalyst may be further enhanced by addition of a noble metal such as Rh, Ru, Pd, Ir or Pt. The catalyst can be broadly used in hydrogen production processes, and is especially suitable for reforming using a membrane which is selective for a predetermined reaction product. Such process can be operated at relatively low temperatures of about 450-700° C. | 2013-11-14 |
20130302242 | GENE SIGNATURES FOR CANCER DIAGNOSIS AND PROGNOSIS - Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided. | 2013-11-14 |
20130302243 | RADIOLABELED NANOSYSTEM, PROCESS FOR THE PREPARATION THEREOF AND ITS USE - Disclosed are novel, targeted, self-assembled nanoparticles radiolabeled with technetium-99m (Tc-99m) as radiodiagnostic compositions, methods of using these compositions and methods for preparing such radiolabeled compositions. Specifically, the compositions of the nanoparticles are composed of self-assembled polyelectrolyte biopolymers having targeting moieties, which can be suitable for targeted delivery of radionuclide metal ions complexed to the nanoparticles. These radiolabeled nanoparticles can specifically bind and internalize into the targeted tumor cells to realize the receptor mediated uptake. Radiolabeled, targeted nanoparticulate composition, methods for making, radiolabeling and using such compositions in the field of diagnosis and therapy are also provided. | 2013-11-14 |
20130302244 | METHOD OF PREPARING IODINE SEED FOR TREATING EYE DISEASE OR CANCER, AND IODINE SEED PREPARED THEREBY - The present invention provides a technique for adsorbing I-125 on a support for treating cancer and a method of preparing an I-125 seed using the same. Since a method of preparing iodine according to the present invention uses an intermediate having phosphate-based, oxalate-based, or arsenate-based anions introduced thereinto, the intermediate has a substitution effect of iodine 3 to 5 times higher than that of a typically used intermediate having chlorine anions introduced thereinto. According to the substitution effect, control of a radiation dose may be possible during the manufacturing of an iodine seed and an iodine seed may be prepared within a shorter period of time. Also, since an amount of residual radioactive iodine may be decreased as a result of a large amount of adsorption, an amount of radioactive iodine (I-125) waste may be decreased, and the effect thereof may be also high environmentally. | 2013-11-14 |
20130302245 | IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS - Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent. | 2013-11-14 |
20130302246 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET - The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target. | 2013-11-14 |
20130302247 | SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF - There are provided, inter alia, methods for diagnosis of the extent of neuroinflammation in a subject. The methods include administering an | 2013-11-14 |
20130302248 | Imaging Agents for Detecting Neurological Disorders - Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders. | 2013-11-14 |
20130302249 | INTESTINAL PEPTIDE TARGETING LIGANDS - Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed. | 2013-11-14 |
20130302250 | SINGLE DOMAIN BINDING MOLECULE - The present invention provides a single domain specific binding molecule having the structure | 2013-11-14 |
20130302251 | EMBOLIC DEVICES - Described herein are apparatus, compositions, systems and methods for occluding vascular structures and vascular malformations with radiopaque hydrogel filaments. The filaments can contain no support members and can be CT and MR compatible. Methods of forming such filaments are also disclosed. | 2013-11-14 |
20130302252 | POLYARGININE-COATED MAGNETIC NANOVECTOR AND METHODS OF USE THEREOF - Polyarginine-coated nanoparticle, and methods for making and using the nanoparticle. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, include one or more of an associated therapeutic agent, targeting agent, and diagnostic agent. | 2013-11-14 |
20130302253 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS - Disclosed is a carrier for the local, targeted administration of a hydrophobic drug. The hydrophobic drug is rendered in to a hydrophilic prodrug thereof, and is contained in the lumen of a thermosensitive liposome or polymersome. Upon administration of the carrier, heat can be applied at the locus where the drug is to be released. After release of the prodrug, it will be activated so as to turn into the active drug. | 2013-11-14 |
20130302254 | ANTIVENOM - The use of scorpion antivenom for the manufacture of a medicament for treatment of hypertension and/or cancer in a subject is disclosed as well as the treatment of the subject. | 2013-11-14 |
20130302255 | NOVEL TARGETED PARAMAGNETIC CONTRAST AGENT - Disclosed are novel, targeting, paramagnetic nanoparticles as contrast agent for magnetic resonance imaging. The compositions of the nanoparticles are composed of self-assembled polyelectrolyte biopolymers having targeting moieties, which can suitable for targeted delivery of paramagnetic ions complexed to the nanoparticles. The nanoparticulate contrast agent can internalize into the targeted tumor cells to realize the receptor mediated uptake, and therefore afford enhanced relaxivity and improved signal-to-noise effect on the examined tissue areas. Methods for making these targeting MRI contrast agents are also provided. | 2013-11-14 |
20130302256 | NANOPARTICULATE MANGANESE MRI CONTRAST AGENTS - This invention discloses a synthetic procedure for preparing nanoparticulate materials of various metal cyanide compounds containing manganese(II) ions in the crystal lattice with the surfaces coated by a hydrophilic compound, and their use as MRI contrast agents with high sensitivity, long blood circulation half lives and low toxicity at low-field and high field MR scanners. | 2013-11-14 |
20130302257 | Compositions and Methods for Delivering Nucleic Acid Molecules and Treating Cancer - The present invention provides compositions and methods for the delivery of nucleic acids to a cell. The present invention additionally provides compositions and methods for the treatment of a disease or disorder, particularly cancer. | 2013-11-14 |
20130302258 | MRI CONTRAST AGENTS - The present invention relates to MRI based imaging. In particular, the present invention provides MRI contrast agents targeted to a HaloTag protein with tunable relaxation properties thereby providing optimal relaxivity for low field strength imaging and the other optimal relaxivity for high field strength imaging. Moreover, the MRI contrast agents are used to detect gene expression (of a gene of interest) in real time in vivo, to detect changes in gene expression (of a gene of interest) over time in, for example, an individual organism, to detect gene expression changes (of a gene of interest) in response to therapeutics, in cell labeling for MR imaging, in clinical diagnostics, and in theranostics. | 2013-11-14 |
20130302259 | EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE - Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described. | 2013-11-14 |
20130302261 | EXOPOLYSACCHARIDE FOR TREATMENT OR CARE OF SKIN, MUCOUS MEMBRANES, HAIR OR NAILS - A method includes administering a cosmetically or dermopharmaceutically effective quantity of exopolysaccharide of a bacterial strain isolated from | 2013-11-14 |
20130302262 | Methods for treating dental diseases, disorders and injuries - Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents. | 2013-11-14 |
20130302263 | BLOCK TYPE-MODIFIED ORGANOPOLYSILOXANE, METHOD FOR USING THE ORGANOPOLYSILOXANE, COSMETIC, AND METHOD FOR PRODUCING THE ORGANOPOLYSILOXANE - A block type organopolysiloxane is represented by the following average composition formula (1), | 2013-11-14 |
20130302264 | INDOLE ALKALOID COMPOUNDS AS MELANOGENESIS PROMOTERS AND USES THEREOF - Provided are indole alkaloid compounds of formula I, for example, pubescine, and the use of such compounds and compositions thereof to promote (e.g., enhance) melanogenesis and pigmentation. | 2013-11-14 |
20130302265 | TOPICAL COMPOSITION AND METHOD FOR SKIN LIGHTENING - A topical cosmetic composition for skin whitening or skin lightening is described. The composition includes an aqueous extract of | 2013-11-14 |
20130302266 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE CATIONIC POLYMER AND AT LEAST TWO CATIONIC SURFACTANTS - The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: (i) one or more cationic polymers, at least one cationic polymer being a dimethyldiallylammonium chloride homopolymer, (ii) two or more than two cationic surfactants, (iii) one or more polysaccharide thickeners, (iv) one or more polyols with a molecular weight of less than 1000. | 2013-11-14 |
20130302267 | HAIR TREATMENT COMPRISING SILICONE GRAFTED STARCH - Hair treatment compositions that can increase the appearance of thicker and fuller hair, by increasing hair volume and root lift. More specifically, it relates to a hair treatment or styling composition including a silicone grafted starch and a film forming polymer. Such compositions can be applied to any areas where a thicker and fuller hair appearance is desired, such as the hair and/or scalp. | 2013-11-14 |
20130302268 | ACTIVE PRINCIPLE FOR MITIGATING UNDESIRED MEDICAL CONDITIONS - A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic centre complying with the formula X | 2013-11-14 |
20130302269 | INSECT ATTRACTANT FORMULATIONS AND INSECT CONTROL - An insect control formulation including methyl eugenol, cue lure and a biodegradable wax carrier is a surprisingly effective attractant for Oriental fruit flies ( | 2013-11-14 |
20130302270 | TUMOR TARGETED TNF-RELATED APOPTOSIS INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR - Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids. | 2013-11-14 |
20130302271 | MUSCLE REPAIR PROMOTER - The present invention relates to muscle repair promoters for local application that contain a colony-stimulating factor (CSF) as an active ingredient. The muscle repair promoters of the present invention exhibit their effect at low doses, particularly when they are administered intramuscularly. | 2013-11-14 |
20130302272 | THERAPEUTIC AGENTS FOR MUSCULAR DYSTROPHY - The present invention provides therapeutic agents for diseases associated with skeletal muscle degeneration comprising a granulocyte colony-stimulating factor (G-CSF) as an active ingredient. The therapeutic agents of the present invention are especially effective as therapeutic agents for muscular dystrophy. | 2013-11-14 |
20130302273 | COMPOSITIONS DERIVED FROM STEM CELL RELEASED MOLECULES & METHODS FOR FORMULATION THEREOF - Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described. | 2013-11-14 |
20130302274 | COMBINATION THERAPY - The present invention is directed to the combination therapy of an afucosylated antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer. | 2013-11-14 |
20130302275 | PH20 Polypeptide Variants, Formulations And Uses Thereof - Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof. | 2013-11-14 |
20130302276 | DISCOVERY OF REGULATORY T CELLS PROGRAMMED TO SUPPRESS AN IMMUNE RESPONSE - A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided. | 2013-11-14 |
20130302277 | METHOD OF TREATMENT - The present invention relates generally to the field of cancer therapy. More particularly, the present invention provides a method for the treatment of gastrointestinal-type cancers and therapeutic agents useful for same. | 2013-11-14 |
20130302278 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS - Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/or TLR agonist). | 2013-11-14 |
20130302279 | IDENTIFICATION OF NATURAL PLANT EXTRACTS HARBORING ANTI-HEPATITIS C VIRUS NS5B POLYMERASE ACTIVITY - The present invention relates to a novel use of naturally occurring plants, mushroom, extracts thereof that exhibit properties as HCV NS5B polymerase inhibitors. | 2013-11-14 |
20130302280 | INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 2013-11-14 |
20130302281 | STABLE LIQUID INTERFERON FORMULATIONS - Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described. | 2013-11-14 |
20130302282 | Inhibitors of Hepatitis C Virus - A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV. | 2013-11-14 |
20130302283 | hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS - This invention encompasses methods, pharmaceutical compositions, and kits for modulating (e.g. reducing) the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury. The invention also encompasses methods, pharmaceutical compositions, and kits for inhibiting the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury. In one embodiment, the umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, lack the production of CD117 or CD45, and do not express hTERT or telomerase. | 2013-11-14 |
20130302284 | MODULATING ONCOLYTIC VSV AND UPREGULATING RAE1 AND NUP98 WITH STATINS - Simvastatin is used to modulate VSV infection at the level of viral replication. Both lipid-lowering and pleiotropic cellular effects of simvastatin are exploited in the modulation. Simvastatin upregulates the expression of Rae1 and Nup98, therefore altering normal cellular mRNA distribution and reverting VSV's mRNA export block. Furthermore, simvastatin causes redistribution of Flotillin-1, which affects VSV replication/budding. Simvastatin is further used as a neoadjuvant for the selective modulatory control of live VSV oncolytic therapy. | 2013-11-14 |
20130302285 | Wharton's Jelly Mesenchymal Stem Cells and Uses Thereof - In one aspect, the invention is directed to methods of expanding hematopoietic stem cells (HSCs) comprising culturing the HSCs with Wharton's Jelly mesenchymal stem cells (WJSCs), a cell culture medium that has been conditioned with WJSCs, or a combination thereof, thereby producing a HSC culture; and maintaining the HSC culture under conditions in which the HSCs expand in the culture, thereby expanding the HSCs. In another aspect, the invention is directed to a method of transplanting the expanded HSCs in an individual in need thereof. In yet another aspect, the invention is directed to compositions comprising HSCs and Wharton's Jelly mesenchymal stem cells (WJSCs). The composition can further comprise a cell culture medium that has been conditioned with WJSCs. | 2013-11-14 |
20130302286 | Modalities for the treatment of degenerative diseases of the retina - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 2013-11-14 |
20130302287 | COMPOSITION FOR ANTI-AGING OR ANTIOXIDANT COMPOSITION CONTAINING PLANT STEM CELL LINE DERIVED FROM CAMBIUM OR PANAX GINSENG INCLUDING WILD GINSENG AND GINSENG AS ACTIVE COMPONENTS - The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of | 2013-11-14 |
20130302288 | Modalities for the treatment of degenerative diseases of the retina - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 2013-11-14 |
20130302289 | Methods for Modulating Immune Responses - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. | 2013-11-14 |
20130302290 | METHODS FOR TREATING A KIDNEY INJURY - Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein. | 2013-11-14 |
20130302291 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION - The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin. | 2013-11-14 |
20130302292 | PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN ALPHA1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR - A peptide having an ED | 2013-11-14 |
20130302293 | COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY - Described herein are compositions, kits and methods for stimulating angiogenic functions of stem cells and/or progenitor cells having pro-angiogenic potential (e.g., endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs)) before transplantation (e.g., ex vivo cell therapy) based on the discovery that functional recovery of CD34+ cells from coronary artery disease (CAD) patients is improved by transfection of antagomirs against one or more miRs of a plurality of miRs identified to be over-expressed in cells from CAD patients. Described herein are methods to recover the functions of EPCs isolated from patients with cardiovascular disease (e.g., CAD or peripheral artery disease (PAD)) by bioengineering the cells with antagomirs and/or premirs to specific micro-RNAs. The bioengineered cells can then be used to treat patients with ischemic or ischemic-related disease (e.g., CAD or PAD) by autologous stem cell therapy. | 2013-11-14 |
20130302294 | Tissue Engineering of Lung - The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery. | 2013-11-14 |
20130302295 | FEEDER-FREE DERIVATION OF HUMAN-INDUCED PLURIPOTENT STEM CELLS WITH SYNTHETIC MESSENGER RNA - The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed. | 2013-11-14 |
20130302296 | Treatment and Prophylaxis for Obsessive Compulsive Disorder - An embodiment is a method of preventing, mitigating or treating Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) that includes administering an effective amount of a medicament comprised of | 2013-11-14 |
20130302297 | MONOUNSATURATED FATTY ACID FOR PREVENTING AND/OR TREATING SKIN COMPLEXION IMPERFECTIONS - The invention relates to the oral or nutraceutical cosmetic use of an effective amount of at least one monounsaturated fatty acid, a salt thereof and/or an ester thereof, as an active agent for treating and/or preventing skin complexion imperfections. | 2013-11-14 |
20130302298 | TREATMENT AND PREVENTION OF ECZEMA - The present invention broadly relates to the use of probiotics for the treatment and prevention of dermatitis. More particularly, the present invention relates to the use of a composition comprising | 2013-11-14 |
20130302299 | NOVEL PROBIOTIC BACILLUS SP. STRAIN - The present invention relates to a novel | 2013-11-14 |
20130302300 | B AND T LYMPHOCYTE ATTENUATOR MARKER FOR USE IN ADOPTIVE T-CELL THERAPY - BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes. | 2013-11-14 |
20130302301 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells. | 2013-11-14 |
20130302302 | DENDRITIC CELLS HAVING ENHANCED YO T-CELL ACTIVATING AND/OR PROLIFERATING ACTIVITY AND METHODS OF PREPARATION OR USE THEREOF - A therapeutic method, which includes administering dendritic cells pulsed in vitro with a bisphosphonate-based bone metabolism improving drug, is provided. The dendritic cells may be capable of efficiently activating and/or proliferating γδ T-cells in vivo and/or in vitro. This can permit for easy proliferation of γδ T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize γδ T-cells. | 2013-11-14 |
20130302303 | PROTEIN KINASE INHIBITORS - Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: | 2013-11-14 |